**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 63627

**Manuscript Type:** META-ANALYSIS

**Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis**

Boonpheng B *et al*. Rituximab *vs* plasmapheresis for prevention of FSGS

Boonphiphop Boonpheng, Panupong Hansrivijit, Charat Thongprayoon, Shennen A Mao, Pradeep K Vaitla, Tarun Bathini, Avishek Choudhury, Wisit Kaewput, Michael A Mao, Wisit Cheungpasitporn

**Boonphiphop Boonpheng,** Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States

**Panupong Hansrivijit,** Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17104, United States

**Charat Thongprayoon,** Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Shennen A Mao,** Division of Transplant Surgery, Mayo Clinic, Jacksonville, FL 32224, United States

**Pradeep K Vaitla,** Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, United States

**Tarun Bathini,** Department ofInternal Medicine, University of Arizona, Tucson, AZ 85721, United States

**Avishek Choudhury,** School of Systems and Enterprises, Stevens Institute of Technology, Hoboken, NJ 07030, United States

**Wisit Kaewput,** Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand

**Michael A Mao,** Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, United States

**Wisit Cheungpasitporn,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Author contributions:** Boonpheng B performed the conceptualization, data curation, formal analysis, investigation, methodology, software, validation, visualization, preparation of original draft, review and editing of manuscript; Hansrivijit P performed the conceptualization, data curation, investigation, visualization, review and editing of manuscript; Thongprayoon C performed the conceptualization, supervision, visualization, review and editing of manuscript; Mao SA supervision, visualization, review and editing of manuscript; Vaitla PK, Bathini T, Mao MA, and Choudhury A performed the project administration; Bathini T, Kaewput W, and Choudhury A performed the project resources; Vaitla PK, Bathini T, Mao MA, Choudhury A, and Kaewput W performed the project supervision, review and editing of manuscript; Mao MA performed the conceptualization; Cheungpasitporn W conceptualization, investigation, methodology, supervision, validation, visualization, review and editing of manuscript; all authors had access to the data, and played a role in writing the manuscript.

**Corresponding author: Wisit Cheungpasitporn, MD, FACP, FASN, FAST, Associate Professor,** Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. wcheungpasitporn@gmail.com

**Received:** January 30, 2021

**Revised:** May 10, 2021

**Accepted:** June 16, 2021

**Published online:**

**Abstract**

BACKGROUND

Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerular diseases leading to renal failure. FSGS has a high risk of recurrence after kidney transplantation. Prevention of recurrent FSGS using rituximab and/or plasmapheresis has been evaluated in multiple small studies with conflicting results.

AIM

To assess the risk of recurrence of FSGS after transplantation using prophylactic rituximab with or without plasmapheresis, and plasmapheresis alone compared to the standard treatment group without preventive therapy.

METHODS

This meta-analysis and systematic review were performed by first conducting a literature search of the MEDLINE, EMBASE, and Cochrane databases, from inception through March 2021; search terms included ‘FSGS,’ ’steroid-resistant nephrotic syndrome’, ‘rituximab,’ and ‘plasmapheresis,’. We identified studies that assessed the risk of post-transplant FSGS after use of rituximab with or without plasmapheresis, or plasmapheresis alone. Inclusion criteria were: Original, published, randomized controlled trials or cohort studies (either prospective or retrospective), case–control, or cross-sectional studies; inclusion of odds ratio, relative risk, and standardized incidence ratio with 95% confidence intervals (CI), or sufficient raw data to calculate these ratios; and subjects without interventions (controls) being used as comparators in cohort and cross-sectional studies. Effect estimates from individual studies were extracted and combined using a random effects model.

RESULTS

Eleven studies, with a total of 399 kidney transplant recipients with FSGS, evaluated the use of rituximab with or without plasmapheresis; thirteen studies, with a total of 571 kidney transplant recipients with FSGS, evaluated plasmapheresis alone. Post-transplant FSGS recurred relatively early. There was no significant difference in recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group, with a pooled risk ratio of 0.82 (95%CI: 0.47-1.45, *I2* = 65%). Similarly, plasmapheresis alone was not associated with any significant difference in FSGS recurrence when compared with no plasmapheresis; the pooled risk ratio was 0.85 (95%CI: 0.60-1.21, *I2*= 23%). Subgroup analyses in the pediatric and adult groups did not yield a significant difference in recurrence risk. We also reviewed and analyzed post-transplant outcomes including timing of recurrence and graft survival.

CONCLUSION

Overall, the use of rituximab with or without plasmapheresis, or plasmapheresis alone, is not associated with a lower risk of FSGS recurrence after kidney transplantation. Future studies are required to assess the effectiveness of rituximab with or without plasmapheresis among specific patient subgroups with high-risk for FSGS recurrence.

**Key Words:** Focal segmental glomerulosclerosis; Kidney transplantation; Meta-analysis; Plasmapheresis; Transplantation; Systematic review

Boonpheng B, Hansrivijit P, Thongprayoon C, Mao SA, Vaitla PK, Bathini T, Choudhury A, Kaewput W, Mao MA, Cheungpasitporn W. Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis. *World J Transplant* 2021; In press

**Core Tip:** Focal segmental glomerulosclerosis (FSGS) is associated with a high risk of recurrence after kidney transplantation. Plasmapheresis and/or rituximab has been used to prevent recurrence with conflicting results. This meta-analysis is among the first to report that the use of preemptive rituximab, either alone or in combination with plasmapheresis, or plasmapheresis alone, did not alter the recurrence risk of FSGS after kidney transplantation.

**INTRODUCTION**

Focal segmental glomerulosclerosis (FSGS) is an important glomerular cause of end-stage kidney disease, and is associated with a high risk of disease recurrence after kidney transplantation[1-5]. Approximately 30% of patients[6,7] develop recurrent FSGS following kidney transplantation, with studies reporting a range between 17% and 55%[8]. FSGS has been shown to negatively affect overall graft survival[9-12]. Although the exact pathogenesis of this disease is unknown, it is believed that circulating factors affecting podocytes and glomerular permeability may play an important role. FSGS recurrence presents early after kidney transplantation; thus, supporting the pathophysiological role of circulating factors.

Treatment for recurrent FSGS in kidney transplant recipients is difficult. Steroids have been used as the main therapy in adults. Unfortunately, only 50% of patients achieve remission following a course of steroid treatment[13]. Furthermore, a large proportion of patients relapse, eventually becoming either steroid-resistant, or steroid-dependent[14]. Plasmapheresis has been effectively used to treat recurrent FSGS after kidney transplantation, purportedly by removing pathophysiological circulating factors and inducing FSGS remission. Preemptive plasmapheresis following kidney transplantation has been proposed as a preventive measure for FSGS.

Rituximab is a monoclonal, chimeric antibody against CD20+ B lymphocytes, and has been used to both prevent and treat recurrent FSGS after kidney transplantation. In 2020, Hansrivijit and Ghahramani[15] reported promising outcomes after treatment of recurrent FSGS in kidney transplant recipients, using either a combination of rituximab and plasmapheresis, or plasma exchange alone. Their study demonstrated an overall remission rate of 72.7%, determined by a significant reduction in serum creatinine levels and the degree of proteinuria. Nevertheless, the efficacy of rituximab or plasmapheresis as a preventive measure for post-transplant recurrent FSGS remains controversial.

This systematic review and meta-analysis were conducted to explore the effectiveness of rituximab–with or without plasmapheresis–compared with plasmapheresis alone, for the prevention of recurrent FSGS after kidney transplantation.

**MATERIALS AND METHODS**

***Search strategy***

This systematic review was conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines[16]. A literature search was performed to identify studies that investigated the effect of preventive use of plasmapheresis and/or rituximab on the risk of recurrent FSGS after kidney transplantation. This was independently conducted by two investigators (Boonpheng B and Hansrivijit P) in the MEDLINE, EMBASE, and Cochrane databases, from inception through March 2021. Search terms included ‘FSGS’, ’steroid-resistant nephrotic syndrome’, ‘rituximab’, and ‘plasmapheresis’.The references of selected articles were manually searched for additional relevant studies. There were nolanguage restrictions.

***Inclusion criteria***

Studies were eligible for inclusion if they met the following criteria: (1) Original, published, randomized controlled cohort (either prospective or retrospective), case-control, or cross-sectional studies; (2) The odds ratio, relative risk, and standardized incidence ratio with 95% confidence intervals (CIs), or sufficient raw data to calculate these ratios, were provided; and (3) Subjects without interventions (controls) were used as comparators in cohort and cross-sectional studies.

Study eligibility was independently assessed by the investigators. Any disagreements were resolved through mutual consensus. The quality of each study was assessed utilizing the Newcastle-Ottawa Quality Scale[17]. This scale assesses each study using three categories: (1) The representativeness of the subjects; (2) The comparability between the study groups; and (3) Ascertainment of the exposure or outcome of interest for case-control and cohort studies respectively.

***Review process and data extraction***

Two investigators independently reviewed the titles and abstracts of all retrieved articles. Articles that did not fulfill the inclusion criteria were excluded. Only potentially relevant articles underwent full-text reviews to determine eligibility. A standardized data collection form was used to extract the following data: First author’s name, year of publication, year of study, country of origin, study design, source of population, number of subjects, baseline characteristics of the subjects, and effect estimates. This data extraction process was performed in duplicate to ensure accuracy.

***Statistical analysis***

All statistical analyses were performed using R version 3.2.0 (the R Foundation for Statistical Computing, Vienna, Austria). The pooled risk ratios for recurrent FSGS in the active intervention group compared with the no intervention group were calculated using the generic inverse method of DerSimonian and Laird[18]. A random effects model was utilized given the high likelihood of between-study variance due to differences in underlying population as well as methodology. Cochran's Q-test, supplemented by the *I2* statistic, was used to evaluate statistical heterogeneity. This statistic quantifies the proportion of total variation across studies due to true heterogeneity rather than chance. An *I2* value of 0-25% represented insignificant heterogeneity, 25%-50% represented low heterogeneity, 50%-75% represented moderate heterogeneity, and > 75% represented high heterogeneity[19].

**RESULTS**

The initial search yielded 813 articles, all of which underwent both title and abstract reviews. Most were excluded at this step as they did not fulfill our inclusion criteria; *i.e.*, they were case reports, letters to the editor, review articles, or interventional studies. A total of 38 studies underwent full-length article review. Of 17 were excluded, as they did not include controls or report the outcome of interest. A total of 21 observational studies, including 920 patients, met our inclusion criteria[8,20-39] and were included in the meta-analysis. Figure 1 outlines our search methodology and selection process. The baseline characteristics of the included studies are summarized in Table 1-4 (detailed characteristics in Tables 3 and 4).

***Preemptive rituximab***

Eleven studies[22-31,39], with a total of 399 kidney transplant recipients with FSGS, evaluated the use of rituximab with or without plasmapheresis. There was no significant difference in recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group, with a pooled risk ratio of 0.82 (95%CI: 0.47-1.45, *I2* = 65%). Figure 2 shows the forest plot.

Subgroup analysis, based on five studies[22-24,30,31] that evaluated preemptive rituximab use without concurrent plasmapheresis compared with no intervention, also showed no significant association; the pooled risk ratio was 0.82 (95%CI: 0.23-2.92, *I2*= 81%).

Four studies[24,29-31] selected only patients deemed to be at high-risk of recurrence, based on demographic and clinical criteria. Only the study by Fornoni *et al*[24] showed a significantly lower recurrence risk in the rituximab group. The remaining three studies reported a numerically higher recurrence in the rituximab group[29-31].

Sensitivity analyses were also performed after excluding five studies[22,23,25,27,28,39] that did not report the rituximab dose or protocol; all were published as abstracts. The risk ratio was also not significant (risk ratio: 1.09, 95%CI: 0.37-3.19).

***Preemptive plasmapheresis***

Thirteen studies[8,20,21,25-27,32-38], including 571 kidney transplant recipients with FSGS, evaluated the use of plasmapheresis alone. Compared with no plasmapheresis, plasmapheresis was not found to be associated with any significant difference in FSGS recurrence, with a pooled risk ratio of 0.85 (95%CI: 0.60-1.21, *I2*= 23%, Figure 3). Subgroup analysis in pediatric patients also did not yield a significant association, with a pooled risk ratio of 0.86 (95%CI: 0.29-4.49, *I2*= 63%).

Sensitivity analysis, after excluding three studies[25,27,34] that were published as abstracts and did not report the protocol or regimen of plasmapheresis, did not show a significant change in the risk ratio (1.07, 95%CI: 0.66-1.72, *I2*=22%).

***Timing of recurrence***

Although only five studies reported the timing of post-transplant recurrent FSGS, it appears that most cases occurred relatively early. Park *et al*[26] reported the time to recurrence in all 6 patients with recurrent FSGS: 3 patients experienced early recurrence, within the first week; 1 experienced a recurrence within the first month; and 3 experienced late recurrence, at 6–12 mo. Verghese *et al*[36] included a Kaplan-Meier curve for FSGS recurrence; this was not significantly different between the two intervention groups, but again showed a trend towards early recurrence. In the study by Alasfar *et al*[29], the median time to recurrence of the entire cohort was 1.25 mo (range: 1 d to 30 mo). Similarly, Auñón *et al*[31] and Uffing *et al*[8] reported the median time to recurrence as 3 and 1.5 mo, respectively. Overall, this data supports the hypothesis that pre-existing circulating factors play a role in FSGS recurrence.

***Effects on allograft function***

Some studies reported decreased allograft survival in patients who experienced FSGS recurrence compared to those who did not[8,26,31-33,35,39]. Allograft survival appears to depend on response to recurrent FSGS therapy, which variably consists of plasmapheresis with more intensive immunosuppressive regimens. Neither pre-emptive plasmapheresis or rituximab *per se* seems to have effects on allograft survival.

***Evaluation for publication bias***

The funnel plots for the outcomes of rituximab and plasmapheresis are shown in Figures 4 and 5, respectively. They are symmetrical, and do not suggest the presence of publication bias in favor of positive studies. Egger’s asymmetry test yielded *P*-values of 0.56 and 0.83 for the rituximab and the plasmapheresis groups, respectively.

**DISCUSSION**

Primary FSGS often recurs after kidney transplantation, leading to graft loss and morbidity[6-8]. Multiple basic science and clinical studies have implicated circulating factors in the pathogenesis of recurrent FSGS[40-42]. The tendency of recurrent FSGS to present early and rapidly after kidney transplantation supports the pathophysiologic role of circulating factors[43]. Case reports of successful kidney allograft transfers from recipients with severe, early, refractory recurrent FSGS, to recipients without a history of primary FSGS, also indirectly suggest the role of circulating factors in disease recurrence[44,45].

Plasmapheresis is considered an effective treatment able to induce remission in established recurrent diseases[46]. Likewise, plasmapheresis has been used as a prevention of FSGS after kidney transplant. By rapidly removing pre-existing circulating factors, especially in conjunction with immunosuppressive medication, it is presumed that some of the putative circulating factors can be eliminated or suppressed to the level low enough not to affect glomerular permeability. Plasmapheresis is performed prior to kidney transplantation in an attempt to prevent FSGS recurrence and associated allograft injury, which may affect graft survival[9,10].

More recently, rituximab has been effectively used to treat many glomerular diseases, including FSGS[47]. The exact mechanism of rituximab in the treatment of FSGS is unknown; however, it is believed that rituximab may have a B-cell-independent effect on podocyte cytoskeletal stabilization, in addition to its B-cell depleting effects[48]. Therefore, rituximab is also utilized to prevent FSGS recurrence, either alone or in combination with plasmapheresis.

Our meta-analysis is among the first to report that the use of preemptive rituximab (either alone or in combination with plasmapheresis) or plasmapheresis alone did not alter the recurrence risk of FSGS after kidney transplantation. To increase power, we combined the patients who received rituximab alone and those who received both rituximab and plasmapheresis into the same group. This might have overestimated the effect of rituximab. However, sensitivity analyses in the subgroup that received rituximab alone or rituximab with plasmapheresis did not change the association so this is unlikely to be significant. The timing of recurrence was also not affected by the preventive measure. In contrast, rituximab and plasmapheresis have been shown to be effective for the treatment of recurrent FSGS after kidney transplantation. The efficacy and safety of combined rituximab and plasmapheresis in patients with recurrent FSGS was recently demonstrated in a meta-analysis, reporting that up to 72.7% of patients achieved remission[15]; of these, most patients achieved complete remission. The authors also described a significant reduction in serum creatinine levels (-0.65 mg/dL) and proteinuria (-4.79 g/d) following treatment[15].

Many studies suggest that recurrent FSGS in kidney transplant recipients is at least partially mediated by circulating factors and/or antibodies[43]. The ineffectiveness of prophylactic rituximab in the prevention of FSGS *via* suppression of antibody production, or plasmapheresis in the removal of pre-formed circulating factors, suggests either circulating factors may be inactive in quiescent FSGS or that removing the putative circulating factors may not be enough to prevent the immunologic cascades that trigger the onset of disease recurrence. It is possible that yet-to-be-identified B-cell-independent immunologic factors may trigger the onset of FSGS recurrence, which leads to production of circulating factors and stimulation of B cells, which are targeted by plasmapheresis and rituximab. The fact that patients who developed FSGS recurrence despite pre-emptive plasmapheresis or rituximab still responded well to plasmapheresis with or without rituximab supports that the initial triggering event is not the putative circulating factors *per se* and is likely B-cell independent.

Beyond plasmapheresis and rituximab, low-density lipoprotein (LDL) apheresis has been evaluated as a preventive strategy for recurrent FSGS in a Japanese study[49]. LDL apheresis removes plasma lipids, a source of oxidative stress, as well as multiple circulating humoral factors that contribute to disease recurrence. The authors reported no FSGS recurrence in five patients using this regimen of pre-transplant LDL apheresis, in addition to rituximab and basiliximab induction; however, this finding should be confirmed by larger studies.

The results of this meta-analysis should be interpreted with attention to the study limitations. First, all included studies were observational in design; thus, the risk of bias was present, and causality could not be established. Second, the sample size of most studies was small. Third, some studies did not report patient characteristics or prognostic factors. Fourth, the treatment regimen, dose of rituximab, and plasmapheresis protocol (frequency, duration, and volume of exchange) were not standardized. Fifth, the use of induction and background immunosuppression varied across studies, depending on the institutional protocol and era of medication availability. Finally, as evidenced by the widely varying recurrence risks reported, it is possible that the different studies enrolled FSGS patients with inherently varying risk of recurrence, resulting in further difficulties regarding the interpretation of post-transplant risk; the eligibility criteria were heterogeneous.

Efforts to elucidate the pathogenic mechanisms of FSGS are ongoing. Further clinical research is therefore required, both to accurately identify the subgroup of patients with FSGS who are at a higher risk for disease recurrence, as well as evaluate preventive interventions within this subgroup. At the time of writing, one ongoing randomized controlled trial (clinical trial number: NCT03763643) was identified, with the primary endpoint of preventing recurrent FSGS through the use of preemptive rituximab plus plasmapheresis or plasmapheresis alone.

**CONCLUSION**

In unselected patients with FSGS, preemptive rituximab with or without plasmapheresis, or plasmapheresis alone, was not associated with a lower risk of FSGS recurrence after kidney transplantation.

**ARTICLE HIGHLIGHTS**

***Research background***

Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerular diseases leading to kidney failure. FSGS has a high risk of recurrence after kidney transplantation. Prevention of recurrent FSGS using rituximab and/or plasmapheresis has been evaluated in multiple small studies with conflicting results.

***Research motivation***

FSGS is associated with a high risk of recurrence after kidney transplantation. Plasmapheresis and/or rituximab has been used to prevent recurrence with conflicting results.

***Research objectives***

This meta-analysis was conducted to assess the effectiveness of rituximab–with or without plasmapheresis–compared with plasmapheresis alone, for the prevention of recurrent FSGS after kidney transplantation.

***Research methods***

This meta-analysis and systematic review were performed by first conducting a literature search of the MEDLINE, EMBASE, and Cochrane databases, from inception through March 2021; search terms included ‘FSGS’, ’steroid-resistant nephrotic syndrome’, ‘rituximab’, and ‘plasmapheresis’. We identified studies that assessed the risk of post-transplant FSGS after use of rituximab with or without plasmapheresis, or plasmapheresis alone.

***Research results***

Eleven studies, with a total of 399 kidney transplant recipients with FSGS, evaluated the use of rituximab with or without plasmapheresis; thirteen studies, with a total of 571 kidney transplant recipients with FSGS, evaluated plasmapheresis alone. Post-transplant FSGS recurred relatively early. There was no significant difference in recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group, with a pooled risk ratio of 0.82 [95% confidence intervals (CI): 0.47-1.45]. Similarly, plasmapheresis alone was not associated with any significant difference in FSGS recurrence when compared with no plasmapheresis; the pooled risk ratio was 0.85 (95%CI: 0.60-1.21). Subgroup analyses in the pediatric and adult groups did not yield a significant difference in recurrence risk. We also reviewed and analyzed post-transplant outcomes including timing of recurrence and graft survival.

***Research conclusions***

The use of rituximab with or without plasmapheresis, or plasmapheresis alone, is not associated with a lower risk of FSGS recurrence after kidney transplantation.

***Research perspectives***

This meta-analysis is among the first to report that the use of preemptive rituximab, either alone or in combination with plasmapheresis, or plasmapheresis alone, did not alter the recurrence risk of FSGS after kidney transplantation.

**REFERENCES**

1 **Bukosza EN**, Kornauth C, Hummel K, Schachner H, Huttary N, Krieger S, Nöbauer K, Oszwald A, Razzazi Fazeli E, Kratochwill K, Aufricht C, Szénási G, Hamar P, Gebeshuber CA. ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS. *Int J Mol Sci* 2020; **21** [PMID: 32197499 DOI: 10.3390/ijms21062095]

2 **Kwiatkowska E**, Stefańska K, Zieliński M, Sakowska J, Jankowiak M, Trzonkowski P, Marek-Trzonkowska N, Kwiatkowski S. Podocytes-The Most Vulnerable Renal Cells in Preeclampsia. *Int J Mol Sci* 2020; **21** [PMID: 32708979 DOI: 10.3390/ijms21145051]

3 **Shuster S**, Ankawi G, Licht C, Reiser J, Wang X, Wei C, Chitayat D, Hladunewich M. Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR. *J Clin Med* 2018; **7** [PMID: 30287750 DOI: 10.3390/jcm7100324]

4 **Dumas De La Roque C**, Prezelin-Reydit M, Vermorel A, Lepreux S, Deminière C, Combe C, Rigothier C. Idiopathic Nephrotic Syndrome: Characteristics and Identification of Prognostic Factors. *J Clin Med* 2018; **7** [PMID: 30205613 DOI: 10.3390/jcm7090265]

5 **Frese J**, Kettwig M, Zappel H, Hofer J, Gröne HJ, Nagel M, Sunder-Plassmann G, Kain R, Neuweiler J, Gross O. Kidney Injury by Variants in the *COL4A5* Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. *Int J Mol Sci* 2019; **20** [PMID: 30691124 DOI: 10.3390/ijms20030519]

6 **Chadban SJ**. Glomerulonephritis recurrence in the renal graft. *J Am Soc Nephrol* 2001; **12**: 394-402 [PMID: 11158232 DOI: 10.1681/ASN.V122394]

7 **Abbott KC**, Sawyers ES, Oliver JD 3rd, Ko CW, Kirk AD, Welch PG, Peters TG, Agodoa LY. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. *Am J Kidney Dis* 2001; **37**: 366-373 [PMID: 11157379 DOI: 10.1053/ajkd.2001.21311]

8 **Uffing A**, Pérez-Sáez MJ, Mazzali M, Manfro RC, Bauer AC, de Sottomaior Drumond F, O'Shaughnessy MM, Cheng XS, Chin KK, Ventura CG, Agena F, David-Neto E, Mansur JB, Kirsztajn GM, Tedesco-Silva H Jr, Neto GMV, Arias-Cabrales C, Buxeda A, Bugnazet M, Jouve T, Malvezzi P, Akalin E, Alani O, Agrawal N, La Manna G, Comai G, Bini C, Muhsin SA, Riella MC, Hokazono SR, Farouk SS, Haverly M, Mothi SS, Berger SP, Cravedi P, Riella LV. Recurrence of FSGS after Kidney Transplantation in Adults. *Clin J Am Soc Nephrol* 2020; **15**: 247-256 [PMID: 31974287 DOI: 10.2215/CJN.08970719]

9 **Artero M**, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. *Am J Med* 1992; **92**: 375-383 [PMID: 1558084 DOI: 10.1016/0002-9343(92)90267-f]

10 **Hariharan S**, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). *Transplantation* 1999; **68**: 635-641 [PMID: 10507481 DOI: 10.1097/00007890-199909150-00007]

11 **Vallianou K**, Marinaki S, Skalioti C, Lionaki S, Darema M, Melexopoulou C, Boletis I. Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience. *J Clin Med* 2021; **10** [PMID: 33498160 DOI: 10.3390/jcm10030373]

12 **Lanaret C**, Anglicheau D, Audard V, Büchler M, Caillard S, Couzi L, Malvezzi P, Mesnard L, Bertrand D, Martinez F, Pernin V, Ducloux D, Poulain C, Thierry A, Del Bello A, Rerolle JP, Greze C, Uro-Coste C, Aniort J, Lambert C, Bouvier N, Schvartz B, Maillard N, Sayegh J, Oniszczuk J, Morin MP, Legendre C, Kamar N, Heng AE, Garrouste C. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. *Am J Transplant* 2021 [PMID: 33512779 DOI: 10.1111/ajt.16504]

13 **Cattran DC**, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. *Am J Kidney Dis* 1998; **32**: 72-79 [PMID: 9669427 DOI: 10.1053/ajkd.1998.v32.pm9669427]

14 **Moranne O**, Watier L, Rossert J, Stengel B; GN-Progress Study Group. Primary glomerulonephritis: an update on renal survival and determinants of progression. *QJM* 2008; **101**: 215-224 [PMID: 18245806 DOI: 10.1093/qjmed/hcm142]

15 **Hansrivijit P**, Ghahramani N. Combined rituximab and plasmapheresis or plasma exchange for focal segmental glomerulosclerosis in adult kidney transplant recipients: a meta-analysis. *Int Urol Nephrol* 2020; **52**: 1377-1387 [PMID: 32306197 DOI: 10.1007/s11255-020-02462-6]

16 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]

17 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

18 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

19 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

20 **Kawaguchi H**, Hattori M, Ito K, Takahashi K, Ota K. Recurrence of focal glomerulosclerosis of allografts in children: the efficacy of intensive plasma exchange therapy before and after renal transplantation. *Transplant Proc* 1994; **26**: 7-8 [PMID: 8109028]

21 **Otsubo S**, Tanabe K, Tokumoto T, Ishikawa N, Shinmura H, Oshima T, Shimizu T, Harano M, Inui M, Shiraga H, Ito K, Fuchinoue S, Nihei H, Toma H. Long-term outcome in renal transplant recipients with focal and segmental glomerulosclerosis. *Transplant Proc* 1999; **31**: 2860-2862 [PMID: 10578316 DOI: 10.1016/s0041-1345(99)00592-8]

22 **Burke GW**, Sageshima J, Fornoni A, Chen L, Abitbol C, Chandar J, Kupin W, Guerra G, Roth D, Shariatmadar S, Zilleruelo G, Ciancio G. Rituximab induction in high risk predominantly pediatric kidney transplant recipients may decrease the incidence and severity of recurrence of focal segmental glomerulosclerosis. *Pediatr Transplan* 2009; **94**

23 **Sagheshima J**, Fornoni A, Wei C, Saenz M, Li J, Mattiazzi A, Ladino M, Kamalaveni P, Ricordi C, Rastaldi MP, Mundel P, Reiser J, Burke GW. Effect of rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor to prevent FSGS recurrence after renal transplantation. *Am J Transplant* 2010; **25** [DOI: 10.1111/j.1600-6143.2010.03024.x]

24 **Fornoni A**, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. *Sci Transl Med* 2011; **3**: 85ra46 [PMID: 21632984 DOI: 10.1126/scitranslmed.3002231]

25 **Miyauchi Y**, Shirakawa H, Shimizu T, Omoto K, Ishida H, Tanabe K. Excellent outcomes of rituximab administration plus plasmapheresis as prophylactic treatment prior to kidney transplantation in patients with focal segmental glomerulosclerosis. *Am J Transplant* 2011; **427** [DOI: 10.1111/j.1600-6143.2011.03534.x]

26 **Park HS**, Hong Y, Sun IO, Chung BH, Kim HW, Choi BS, Park CW, Jin DC, Kim YS, Yang CW. Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients. *Korean J Intern Med* 2014; **29**: 482-488 [PMID: 25045296 DOI: 10.3904/kjim.2014.29.4.482]

27 **Okumi M**, Miyauchi Y, Yagisawa T, Unagami K, Toki D, Omoto K, Ishida H, Tanabe K. Excellent outcomes of prophylactic rituximab administration with plasmapheresis in kidney transplant recipients with focal segmental glomerulosclerosis. *Am J Transplant* 2015

28 **Futamura K**, Okada M, Nagai T, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Narumi S, Watarai Y. Recurrent focal segmental glomerular sclerosis after renal transplantation; prevention and treatment with Rituximab. *Transplant* 2016; S658 [DOI: 10.1097/01.tp.0000490147.72544.1a]

29 **Alasfar S**, Matar D, Montgomery RA, Desai N, Lonze B, Vujjini V, Estrella MM, Manllo Dieck J, Khneizer G, Sever S, Reiser J, Alachkar N. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation. *Transplantation* 2018; **102**: e115-e120 [PMID: 29189487 DOI: 10.1097/TP.0000000000002008]

30 **Lu Y,** Lyons J, Tischer S, Woodside K, Park J. Efficacy and safety of a single-dose rituximab for prevention of focal segmental glomerulosclerosis recurrence after kidney transplant. *Am J Transplant* 2018; 801 [DOI: 10.1111/ajt.14918]

31 **Auñón P**, Polanco N, Pérez-Sáez MJ, Rodrigo E, Sancho A, Pascual J, Andrés A, Praga M. Pre-emptive rituximab in focal and segmental glomerulosclerosis patients at risk of recurrence after kidney transplantation. *Clin Kidney J* 2021; **14**: 139-148 [PMID: 33564412 DOI: 10.1093/ckj/sfz120]

32 **Iguchi Y**, Tanabe K, Yagisawa T, Fuchinoue S, Kawai T, Kawaguchi H, Takahashi K, Ito K, Toma H, Agishi T, Ota K. Plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis of kidney allograft in adult recipients. *Ther Apher* 1997; **1**: 191-194 [PMID: 10225770 DOI: 10.1111/j.1744-9987.1997.tb00040.x]

33 **Ohta T**, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K. Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. *Transplantation* 2001; **71**: 628-633 [PMID: 11292291 DOI: 10.1097/00007890-200103150-00008]

34 **Somers MJG,** Baum MA. Pre-transplant conditioning with plasmapheresis and cyclosporine infusion reduces recurrence of focal segmental glomerulosclerosis (fsgs) in children. *Pediatr Transplant* 2009; 96

35 **Gonzalez E**, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. *Pediatr Transplant* 2011; **15**: 495-501 [PMID: 21338460 DOI: 10.1111/j.1399-3046.2011.01478.x]

36 **Verghese PS**, Rheault MN, Jackson S, Matas AJ, Chinnakotla S, Chavers B. The effect of peri-transplant plasmapheresis in the prevention of recurrent FSGS. *Pediatr Transplant* 2018; **22**: e13154 [PMID: 29388290 DOI: 10.1111/petr.13154]

37 **Koyun M**, Çomak E, Akman S. Peri-transplant Plasmapheresis in FSGS. *Pediatr Transplant* 2019; **23**: e13322 [PMID: 30450731 DOI: 10.1111/petr.13322]

38 **Campise M**, Favi E, Messa P. Clinical Outcomes of Prophylactic and Therapeutic Plasmapheresis in Adult Deceased-Donor Kidney Transplant Recipients With Primary Focal Segmental Glomerulosclerosis. *Exp Clin Transplant* 2019; **17**: 461-469 [PMID: 30570457 DOI: 10.6002/ect.2018.0106]

39 **Mukku VK,** Hussain S, Mujtaba MA. 201 Overview of Recurrence of Focal Segmental Glomerulosclerosis in Renal Transplant Patients and Effectiveness of Preemptive Plasma Exchange and Rituximab in Preventing Recurrence. *Am J Kidney Dis* 2021; 630 [DOI: 10.1053/j.ajkd.2021.02.206]

40 **Savin VJ**, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. *N Engl J Med* 1996; **334**: 878-883 [PMID: 8596570 DOI: 10.1056/NEJM199604043341402]

41 **Le Berre L**, Godfrin Y, Günther E, Buzelin F, Perretto S, Smit H, Kerjaschki D, Usal C, Cuturi C, Soulillou JP, Dantal J. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. *J Clin Invest* 2002; **109**: 491-498 [PMID: 11854321 DOI: 10.1172/JCI12858]

42 **Delville M**, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. *Sci Transl Med* 2014; **6**: 256ra136 [PMID: 25273097 DOI: 10.1126/scitranslmed.3008538]

43 **Kienzl-Wagner K**, Waldegger S, Schneeberger S. Disease Recurrence-The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis. *Front Immunol* 2019; **10**: 1669 [PMID: 31379860 DOI: 10.3389/fimmu.2019.01669]

44 **Gallon L**, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. *N Engl J Med* 2012; **366**: 1648-1649 [PMID: 22533598 DOI: 10.1056/NEJMc1202500]

45 **Kienzl-Wagner K**, Rosales A, Scheidl S, Giner T, Bösmüller C, Rudnicki M, Oberhuber R, Margreiter C, Soleiman A, Öfner D, Waldegger S, Schneeberger S. Successful management of recurrent focal segmental glomerulosclerosis. *Am J Transplant* 2018; **18**: 2818-2822 [PMID: 29962080 DOI: 10.1111/ajt.14998]

46 **Kashgary A**, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, Clark WF. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. *BMC Nephrol* 2016; **17**: 104 [PMID: 27473582 DOI: 10.1186/s12882-016-0322-7]

47 **Santos JE**, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C. Rituximab use in adult glomerulopathies and its rationale. *J Bras Nefrol* 2020; **42**: 77-93 [PMID: 31904761 DOI: 10.1590/2175-8239-JBN-2018-0254]

48 **Gauckler P**, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? *Autoimmun Rev* 2020; **19**: 102671 [PMID: 32942039 DOI: 10.1016/j.autrev.2020.102671]

49 **Sannomiya A**, Murakami T, Koyama I, Nitta K, Nakajima I, Fuchinoue S. Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation. *J Transplant* 2018; **2018**: 8926786 [PMID: 29808114 DOI: 10.1155/2018/8926786]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 30, 2021

**First decision:** May 5, 2021

**Article in press:**

**Specialty type:** Transplantation

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Ban TH, Rijkse E, Rostaing L **S-Editor:** Fan JR **L-Editor: P-Editor:**


**Figure Legends**




**Figure 1 Outline of search methodology, PRISMA 2009 flow diagram.**




**Figure 2 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group.**



**Figure 3 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between patients who did and did not receive plasmapheresis.**



**Figure 4 Funnel plot evaluating publication bias regarding the effects of rituximab on focal segmental glomerulosclerosis recurrence.**



**Figure 5 Funnel plot evaluating publication bias regarding the effects of plasmapheresis on focal segmental glomerulosclerosis recurrence.**

**Table 1 Characteristics of included studies evaluating the outcomes of preemptive plasmapheresis**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Design** | ***n* (%)** | **Population** | **Age** | **PP protocol** | **Def of recurrence** | **Recurrence** | **Graft survival** | **Quality assessment** |
| Kawaguchi *et a*l[20], 1994 | Japan | Retrospective | 14 | FSGS children | 2-12 yr at FSGS Dx | 2-3 sessions immediately before KT (-5, -3, and -1 d) ATG 7-14 d pre-op | N/A | 3/8 (38%) *vs* 4/6 (67%) | 93% graft survival in overall cohort | Fair, 4-1-2 |
| Otsubo *et al*[21], 1999 | Japan | Retrospective | 37 | FSGS undergoing KT | 22 yr at KT | N/A | Clinical and biopsy in all cases | 4/19 (21%) *vs* 9/18 (50%) | 75%  at 5 yr, 63% at 10 yr | Fair, 4-1-2 |
| Iguchi *et al*[32], 1997 | Japan | Prospective cohort | 11 | FSGS undergoing KT | 33.3 (20-43) yr | 3 sessions of pre-op PP within 3 d before KT | Clinical and/or pathologic | 1/3 (33%) *vs* 4/8 (50%) | 100% *vs* 63.6% | Fair, 4-2-2 |
| Ohta *et al*[33], 2001 | Japan | Retrospective | 21 | FSGS children | Age of FSGS onset 69.5 ± 36.4 mo (range 9-134 mo) | 1-2 sessions immediately before KT (-5, -3, and -1 d). Therapeutic PP until reduction of proteinuria | Clinical and/or pathologic | 5/15 (33%) *vs* 4/6 (67%) | 13/15 *vs* 3/5 (1 death with functioning graft in Non-PP) | Fair, 4-2-2 |
| Somers and Baum[34], 2009 | United States | Retrospective | 52 | FSGS children | 12.5 yr | N/A | N/A | 5/19 (26%) *vs* 18/33 (55%) | Overall, 11/52 graft loss | Fair, 4-1-2 |
| Gonzalez *et al*[35], 2011 | United States | Retrospective | 34 | FSGS children | Age at KT: 13 ± 5 yr. Age at FSGS diagnosis: 5.3 yr (*n* = 19, recurrence group), 6.9 yr (*n* = 15, no recurrence group) | 1-10 sessions | Clinical and/or pathologic | 9/17 (53%) *vs* 10/17 (59%) | Graft loss at 3 yr: 25% in recurrence group *vs* 20% in non-recurrence | High, 4-2-3 |
| Miyauchi *et al*[25], 2011 | Japan | Prospective cohort | 25 | FSGS undergoing KT | N/A | N/A | N/A | 3/9 (33%) *vs* 2/4 (50%) | N/A | Low, 3-1-1 |
| Park *et al*[26], 2014 | South Korea | Retrospective | 27 | FSGS undergoing KT | Age at KT: 39 ± 14 yr and 36 ± 11 yr | PP and IVGV infusion after each session of PP prior to transplantation | Clinical confirmed by biopsy | 1/4 (25%) *vs* 5/18 (27%) | FSGS with recurrence had less graft survival than those without recurrence (*P* = 0.01) | High, 4-2-3 |
| Okumi *et al*[27], 2015 | Japan | Retrospective | 38 | FSGS undergoing KT | N/A | N/A | N/A | 4/10 (40%) *vs* 2/5 (40%) | 5/38 graft loss overall | Low, 3-1-1 |
| Verghese *et al*[36], 2018 | United States | Retrospective | 57 | FSGS children | Age at KT: 13.2 ± 4.5 yr (after 2006 with PP) *vs* 10.4 ± 5.4 yr (before 2006, no PP) | LDKT: 3 sessions PP pre-op. DDKT: 1 session of PP pre-op. Post-op: 5 sessions of PP every other day starting POD1 | Biopsy; if unable to do biopsy, persistent nephrotic range proteinuria | 7/26 (27%) *vs* 8/31 (26%) | Death-censored graft survival not sig different (*P* = 0.61) | High, 4-2-3 |
| Koyun *et al*[37], 2019 | Turkey | Retrospective | 46 | FSGS children | Age at KT: 7.2 ± 1.2 yr (PP) *vs* 10.7 ± 4.5 yr (no PP) | LDKT: 2-5 sessions of PP pre-op. DDKT: 1 session of PP pre-op. Post-op: 5 session of early PP | N/A | 3/6 (50%) *vs* 5/40 (12.5%) | N/A | Low, 3-1-1 |
| Campise *et al*[38], 2019 | Italy | Retrospective | 73 | FSGS undergoing KT | Age at FSGS Dx: 27 (15-35) yr. Age at KT: 41 (38-52) yr | 2003-2008: post-transplant PP only 2008-2014: 1 session immediately before surgery and 3 sessions *per* week for 3 consecutive weeks from POD1 | Post-transplant proteinuria; confirmed by biopsy | Biopsy-proven: 5/21 (24%) *vs* 12/52 (23%) | Death-censored graft survival: 81% (17/21) *vs* 84% (44/52) (*P* = 0.7022) | High, 4-2-3 |
| Uffing *et al*[8], 2020 | United States, Europe, Brazil | Retrospective, multicenter | 176 | FSFS adults undergoing KT | Age at KT: 38 (29–47) yr. Age at FSGS Dx: 27 (17-40) yr | N/A | N/A | 9/22 (41%) *vs* 48/154 (31%) | Graft failure 15% w/o recurrence and 39% with recurrence | High, 4-2-3 |

N: Number; ESKD: End-stage kidney disease; FSGS: Focal segmental glomerulosclerosis; PP: Plasmapheresis; KT: Kidney transplantation; RTX: Rituximab; N/A: Not available.

**Table 2 Characteristics of included studies evaluating the outcomes of preemptive rituximab**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Design** | ***n* (%)** | **Population** | **Age** | **Rituximab dose and protocol** | **Concurrent PP** | **Def of recurrence** | **Recurrence** | **Graft survival** | **Follow-up duration** | **Quality assessment** |
| Burke *et al*[22], 2009 | United States | Retrospective | 29 | FSGS undergoing KT | Age at KT: 6-21 yr | N/A | No | New onset proteinuria | 6/18 (33%) *vs* 8/11 (72%) | No significant difference in graft survival | N/A | Fair, 3-1-2 |
| Sagheshima *et al*[23], 2010 | United States | Prospective | 40 | FSGS undergoing KT | Age at KT: 4-24 yr | N/A | No | UPCR > 3.5 post-transplant | 8/29 (28%) *vs* 7/11 (64%) | N/A | N/A | Low, 3-1-1 |
| Fornoni *et al*[24], 2011 | United States | Retrospective | 41 | High-risk pediatric/young adult FSGS undergoing KT: (< 25 yr at FSGS Dx or progression to ESKD within 7 yr) | Age at KT: 15 ± 5.5 yr (rituximab), 12.3 ± 5.2 yr (control) | One dose of rituximab (375 mg/m2) within 24 h of kidney transplantation | No | UPCR > 3.5 within 30 d post-transplant or need for PP. Protocol biopsy in 20/27 (74%) | 7/27 (26%) *vs* 9/14 (64%) | 1-yr graft survival: 95.8% *vs* 85.7% (*P* = 0.26) | N/A | High, 4-1-3 |
| Miyauchi *et al*[25], 2011 | Japan | Prospective | 25 | FSGS undergoing KT | N/A | N/A | N/A | N/A | 2/12 (17%) *vs* 5/13 (38%) | N/A | N/A | Low, 3-1-1 |
| Park *et al*[26], 2014 | South Korea | Retrospective | 27 | FSGS undergoing KT | Age at KT: 39 ± 14 yr (*n* = 7, recurrence), 36 ± 11 yr (*n* = 20, no recurrence) | PP and IVGV infusion after each session of PP prior to transplantation, and RTX (375 mg/m2) was administered  within 1 wk prior to transplantation | Yes | Clinical confirmed by biopsy | 1/4 (25%) *vs* 5/18 (27%) | FSGS with recurrence had less graft survival than those without recurrence (*P* = 0.01) | N/A | High, 4-1-3 |
| Okumi *et al*[27], 2015 | Japan | Retrospective | 38 | FSGS undergoing KT | N/A | N/A | Yes | N/A | 5/23 (22%) *vs* 6/15 (40%) | 5/38 graft loss overall. Cr at yr 2 and 6 significantly lower in those who received both R + PP | N/A | Low, 3-1-1 |
| Futamura *et al*[28], 2016 | Japan | Retrospective | 28 | FSGS undergoing KT | N/A | N/A | Yes | N/A | 3/7 (43%) *vs* 5/21 (24%) | N/A | N/A | Low, 3-1-1 |
| Alasfar *et al*[29], 2018 | United States | Prospective | 64 | High-riskFSGS undergoing KT (2 of: white, age ≤ 30 at Dx, progression to ESKD ≤ 5 yr. Albumin < 3 g/dL during disease course, h/o failed KT due to recurrence) | Age at FSGS Dx: 29.9 ± 17.2. Age at KT: 38 ± 16.5 | Rituximab was given in 1 or 2 doses (375 mg/m2 *per* dose) | Yes; 3-10 sessions of PP day-7 to POD 2 | Clinical and biopsy | 23/37 (62%) *vs* 14/27 (51%) | Trend toward better renal allograft survival in nonrecurrent group compared  to the recurrent group (*P* = 0.0662) | 29.5 mo | High, 4-1-3 |
| Lu *et al*[30], 2018 | United States | Retrospective | 55 | High-riskFSGS undergoing KT considered (age ≤ 25 at Dx, proteinuria ≥ 5 g/d, progression to ESKD ≤ 5-7 yr) | Age at KT: 44 | One dose of rituximab (375 mg/m2, max 100 mg) | No | Proteinuria and biopsy | 4/7 (57%) *vs* 6/48 (13%) | Graft loss: 1/7 (14%) *vs* 8/48 (17%) | N/A | Fair, 3-2-2 |
| Auñón *et al*[31], 2021 | Spain | Retrospective, multicenter | 34 (93 total cohort) | High-riskFSGS undergoing KT considered (hypoalbuminemia and NS at baseline); genetic form excluded | Age at KT: 35.0 ± 15.2 (R group), 42.4 ± 12.2 (non-R group) | Rituximab, 1 g at induction and 1 g on day 14 after transplantation | No | Recurrence of proteinuria, confirmed by biopsy | 6/12 (50%) *vs* 9/22 (41%) | 53.5% with recurrence *vs* 88.5% in non-recurrence group | N/A | High, 4-1-3 |
| Mukku *et al*[39], 2021 | United States | Retrospective | 18 | FSGS undergoing KT | Age at KT: 35 yr | N/A | Yes | Recurrence of proteinuria | 0/8 *vs* 3/10 (30%) | 8/8 *vs* 9/10 | 30 (1-36) mo | Low, 3-1-1 |

N: Number; ESKD: End-stage kidney disease; FSGS: Focal segmental glomerulosclerosis; PP: Plasmapheresis; KT: Kidney transplantation; RTX: Rituximab; N/A: Not available.

**Table 3 Detailed characteristics of included studies evaluating the outcomes of preemptive plasmapheresis**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Age** | **Genetic testing** | **Race** | **Time to ESKD** | **Repeat KT** | **Induction** | **IS** | **Donor types** | **Biopsy** | **Follow-up duration** |
| Kawaguchi *et a*l[20], 1994 | Japan | 2-12 yr at FSGS Dx | N/A | Asian | 12–117 mo |  | ATG only in PP group | CS, CsA, AZA/mizolibine | 13/14 living1/14 DDKT | N/A | N/A |
| Otsubo *et al*[21], 1999 | Japan | 22 yr at KT | N/A | Asian | N/A | N/A | CS, CsA/Tac | CS, CsA/Tac, AZA/mizolibine | 34/37 LRKT, 4/37 DDKT | Per-cause biopsy | N/A |
| Iguchi *et al*[32], 1997 | Japan | 33.3 (20-43) yr | N/A | Asian | N/A | None | ATG during first 2 wk in PP group | CS, CsA, AZA | 100% LRKT | Intra-op biopsy (1 h) in all cases then as clinically indicated | N/A |
| Ohta *et al*[33], 2001 | Japan | Age of FSGS onset  69.5 ± 36.4 mo (range 9-134 mo) | N/A | Asian | 51.8 ± 29.6 mo (range 7-120) | 1/21 | None | CS, CsA/Tac, AZA/mizolibine | 3/21 DDKT (14%) *vs* 18/21 (LRKT) | Intra-op biopsy (1 h) in all cases then as clinically indicated | 62.7 (PP group), 41.6 mo (non-PP group) |
| Somers and Baum[34], 2009 | Unite States | 12.5 yr (85% white) | N/A | 85% White | 3 yr (median) | N/A | N/A | CsA-based regimen | 42% living donor | N/A | N/A |
| Gonzalez *et al*[35], 2011 | United States | Age at KT: 13 ± 5 yr | NPHS2 mutation testing on 10 patients (9 tested negative, 1 with heterozygous mutation) | 29% White, 15% African, 44% Hispanic, 12% others | 4.2 yr (*n* = 19, recurrence group), 3.1 yr (*n* = 15, no recurrence group) | Recurrence in previous graft 5/34 | rATG (if ATN) or daclizumab | CS, CsA/Tac, MMF | 15/34 living, 19/34 DDKT | Per-cause biopsy | N/A |
| Miyauchi *et al*[25], 2011 | Japan | N/A | N/A | Asian | N/A | N/A | N/A | CS, CsA/Tac, AZA/mizolibine | N/A | N/A | N/A |
| Park *et al*[26], 2014 | South Korea | Age at KT: 39 ± 14 yr (*n* = 7, recurrence), 36 ± 11 yr (*n* = 20, no recurrence) | N/A | Asian | 46 ± 44 mo (*n* = 7, recur group), 68 ± 67 mo (*n* = 20, no recur group) | none | Basiliximab (20 mg) on days 0 and 4 | CS, CsA/Tac, MMF | 4/27 DDKT, 24/27 living (17/27 LRKT) | Per-cause biopsy | N/A |
| Okumi *et al*[27], 2015 | Japan | N/A | N/A | Asian | N/A | N/A | Basiliximab (after 2002) | CS, CsA/Tac, MMF | N/A | N/A | N/A |
| Verghese *et al*[36], 2018 | United States | Age at KT: 13.2 ± 4.5 yr (after 2006 with PP) *vs* 10.4 ± 5.4 yr (before 2006, no PP) | NPHS2 mutation testing (for those with NPHS2 homozygous mutation, PP not indicated) | N/A | N/A | N/A | 93% received lymphocyte depleting induction | Before 2006: AZA (90%), MMF (16%), CsA (97%), CS (97%). After 2006: AZA (12%), MMF (88%), CsA (62%)/Tac (38%), CS (12%) | DDKT 37% *vs* Living 63% | Per-cause biopsy | N/A |
| Koyun *et al*[37], 2019 | Turkey | Age at KT: 7.2 ± 1.2 yr (PP) *vs* 10.7 ± 4.5 yr (no PP) | Genetic testing (unspecified gene panel): 2/6 + in PP group *vs* 14/40+ in control group | N/A | N/A | N/A | N/A | N/A | DDKT 20%, Living 80% | N/A | N/A |
| Campise *et al*[38], 2019 | Italy | Age at FSGS Dx: 27 (15-35) yr. Age at KT: 41 (38-52) yr | Not done | 100% White | 5 (1-10) yr, 33% rapid (< 3 yr) progression to ESKD | (7/21) 33% in PP group; previous graft loss due to recurrence | Basiliximab (20 mg) on days 0 and 4 | CS, Tac, MMF | 100% DDKT | Per-cause biopsy | 45 (30-107) mo |
| Uffing *et al*[8], 2020 | Unites States, Europe, Brazil | Age at KT: 38 (29–47) yr. Age at FSGS Dx: 27 (17-40) yr | Not done in most patients | 56% White, 11% Black, 5% Hispanic, 5% Asian, 10% mixed, Other or unknown 14% | 38 (14–75) mo | 25%; prior graft loss due to FSGS 9% | rATG (42%), basiliximab (42%), daclizumab (3%), none (13%) | CS + Tac + MMF (72%), CS + CsA + MMF (17%), Tac + MMF (5%), other 6% | 67% DDKT, 22% LRKT, 15% LUKT | Per-cause biopsy | N/A |

N: Number; ESKD: End-stage kidney disease; FSGS: Focal segmental glomerulosclerosis; PP: Plasmapheresis; KT: Kidney transplantation; RTX: Rituximab; N/A: Not available; LUKT: Living-related kidney transplantation; CS: Corticosteroids; CsA: Cyclosporine; Tac: Tacrolimus; MMF: Mycophenolate mofetil; AZA: Azathioprine; rATG: Rabbit anti-thymocyte globulin; DDKT: Deceased donor kidney transplantation; LRKT: Living-related kidney transplantation.

**Table 4 Detailed characteristics of included studies evaluating the outcomes of preemptive rituximab**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Age** | **Genetic testing** | **Race** | **Time to ESKD** | **Repeat KT** | **Induction** | **IS** | **DDKT** | **Follow-up duration** |
| Burke *et al*[22], 2009 | United States | Age at KT: 6-21 yr | N/A | N/A | N/A | N/A | rATG or daclizumab | CS, Tac, MMF | N/A | N/A |
| Sagheshima *et al*[23], 2010 | United States | Age at KT: 4-24 yr | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Fornoni *et al*[24], 2011 | United States | Age at KT: 15 ± 5.5 yr (rituximab), 12.3 ± 5.2 yr (control) | N/A | White 56%, Black 44% | 3.4 ± 2.0 yr (rituximab group), 3.3 ± 2.1 (control) | N/A | Combined thymoglobulin (1 mg/kg, 3–5 doses) and daclizumab. Alemtuzumab in one patient. | CS, Tac, MMF | Preemptive: 3/27 (11%) in rituximab group, 2/14 (14%) in non-rituximab group | N/A |
| Miyauchi *et al*[25], 2011 | Japan | FSGS undergoing KT | N/A | Asian | N/A | N/A | N/A | CS, CsA/Tac, AZA/mizolibine | N/A | N/A |
| Park *et al*[26], 2014 | South Korea | Age at KT: 39 ± 14 (*n* = 7, recurrence), 36 ± 11 (*n* = 20, no recurrence) | N/A | Asian | 46 ± 44 mo (*n* = 7, recur group), 68 ± 67 mo (*n* = 20, no recur group) | none | Basiliximab (20 mg) on days 0 and 4 | CS, CsA/Tac, MMF | 3/27 DDKT, 24/27 living | N/A |
| Okumi *et al*[27], 2015 | Japan | N/A | N/A | Asian | N/A | N/A | Basiliximab (after 2002) | CS, CsA/Tac, MMF | N/A | N/A |
| Futamura *et al*[28], 2016 | Japan | N/A | N/A | Asian | N/A | N/A | N/A | N/A | N/A | N/A |
| Alasfar *et al*[29], 2018 | United States | Age at FSGS Dx: 29.9 ± 17.2. Age at KT: 38 ± 16.5 | N/A | White 56%, Black 32%, Asian 7%, Hispanic 4% | 4 (0–9) yr | 37% (42/66 63% first transplant) | Depleting agent 92% | CS + Tac + MMF (92%), CS + CsA + MMF (8%) | DDKT 37%, LUKT 37%, LRKT 25% | 29.5 mo |
| Lu *et al*[30], 2018 | United States | Age at KT: 44 | N/A | White 64% | N/A | 0% | N/A | CS, Tac, MMF | N/A | N/A |
| Auñón *et al*[31], 2021 | Spain | Age at FSGS Dx: 24.5 ± 18.5 (rituximab group), 30 ± 13.7 (non-rituximab group). Age at KT: 35.0 ± 15.2 (R group), 42.4 ± 12.2 (non-R group) | Excluded suspected genetic causes of FSGS | N/A | 5.12 ± 4.44 (R group), 7.58 ± 7.11 (Non-R group) | 7/34 (21%); recurrence in previous graft 2/12 (16.7%) in R group *vs* 2/22 (9.1%) In non-R group | Rituximab group: rATG 16.7%, basiliximab 50%. Non-rituximab group: rATG 40.9%, basiliximab 22.7% | CS + Tac + MMF (93.3%) | 85.3% DDKT, 11.8% LRKT, 2.9% LUKT | N/A |
| Mukku *et al*[39], 2021 | United States | Age at KT: 35 yr | N/A | White 39%, Black 27% | N/A | 2/8 pre-emptive group *vs* 0/10 | rATG (61%), alemtuzumab (22%), basiliximab (17%) | CS + Tac + MMF (83%), CS + CsA + MMF (17%) | 89% DDKT | 30 (1-36) mo |

N: Number; ESKD: End-stage kidney disease; FSGS: Focal segmental glomerulosclerosis; RRT: Renal replacement therapy; PP: Plasmapheresis; IS: Immunosuppression; KT: Kidney transplantation; RTX: Rituximab; CS: Corticosteroids; CsA: Cyclosporine; Tac: Tacrolimus; MMF: Mycophenolate mofetil; AZA: Azathioprine; rATG: Rabbit anti-thymocyte globulin; DDKT: Deceased donor kidney transplantation; LRKT: Living-related kidney transplantation; LUKT: Living-related kidney transplantation; N/A: Not available.